Navigating the future of Alzheimer's care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems
BMC Health Serv Res. 2024 Jun 5;24(1):705. doi: 10.1186/s12913-024-11019-7.
ABSTRACT
BACKGROUND: A new class of antibody-based drug therapy with the potential for disease modification is now available for Alzheimer's disease (AD). However, the complexity of drug eligibility, administration, cost, and safety of such disease modifying therapies (DMTs) necessitates adopting new treatment and care pathways. A working group was convened in Ireland to consider the implications of, and health system readiness for, DMTs for AD, and to describe a service model for the detection, diagnosis, and management of early AD in the Irish context, providing a template for similar small-medium sized healthcare systems.
METHODS: A series of facilitated workshops with a multidisciplinary working group, including Patient and Public Involvement (PPI) members, were undertaken. This informed a series of recommendations for the implementation of new DMTs using an evidence-based conceptual framework for health system readiness based on [1] material resources and structures and [2] human and institutional relationships, values, and norms.
RESULTS: We describe a hub-and-spoke model, which utilises the existing dementia care ecosystem as outlined in Ireland's Model of Care for Dementia, with Regional Specialist Memory Services (RSMS) acting as central hubs and Memory Assessment and Support Services (MASS) functioning as spokes for less central areas. We provide criteria for DMT referral, eligibility, administration, and ongoing monitoring.
CONCLUSIONS: Healthcare systems worldwide are acknowledging the need for advanced clinical pathways for AD, driven by better diagnostics and the emergence of DMTs. Despite facing significant challenges in integrating DMTs into existing care models, the potential for overcoming challenges exists through increased funding, resources, and the development of a structured national treatment network, as proposed in Ireland's Model of Care for Dementia. This approach offers a replicable blueprint for other healthcare systems with similar scale and complexity.
PMID:38840115 | DOI:10.1186/s12913-024-11019-7
Authors
![Iracema Leroi](/sites/default/files/styles/image_1x1_small/public/profile/iracema_leroi.jpg?h=87136cbf&itok=7wZy3PzU)
Iracema Leroi, MD, FRCPC, MRCPsych
Professor in Geriatric Psychiatry
![Sean Kennely](/sites/default/files/styles/image_1x1_small/public/profile/sean_kennelly.jpg?h=87136cbf&itok=PkvsZpjF)
Sean Kennelly MB PhD FRCPI
Clinical Associate Professor of Medical Gerontology
![Irina Kinchin](/sites/default/files/styles/image_1x1_small/public/profile/irina_kinchin.jpg?h=1dcbba13&itok=whH9YZnw)
Irina Kinchin, PhD, MSc
Health Economist
![Seán O’Dowd](/sites/default/files/styles/image_1x1_small/public/profile/Se%C3%A1n%20O%E2%80%99Dowd.jpg?h=2a8f70e4&itok=OlK42WEH)
Seán O’Dowd, BSc (Pharm), MB BCh, MD, MRCPI
Consultant Neurologist
![Dominic Trepel](/sites/default/files/styles/image_1x1_small/public/profile/dominic_trepel.jpg?h=404dafc1&itok=emOQKR1b)
Dominic Trépel, PhD
Assistant Professor of Health Economics